Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study



Summary

A multicenter study investigated the impact of extranodal (EN) disease involvement on outcomes after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma (LBCL) patients. The study found that EN disease, particularly in specific sites like the central nervous system or bone marrow, was associated with inferior progression-free survival (PFS) and overall survival (OS) after CAR T-cell therapy. Higher EN disease burden also negatively impacted outcomes. These findings suggest that EN disease is an important prognostic factor to consider when assessing suitability for CAR T-cell therapy in LBCL patients and may warrant more intensive pre- or post-CAR T-cell strategies.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!